Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyCommunity-Care Tezspire Coverage Update | OpenPaye…
    Ask Trek AI about this page
    CurrentCommunity-CarePolicy N/A

    Tezspire (tezepelumab) Medical Benefit Medication Utilization Policy

    Customize your policy alerts

    Sign up for all Community-Care policy alerts

    Know when Community-Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage, initial and continuation criteria, quantity limits, authorization periods, and applicable billing code for tezepelumab for severe asthma and chronic rhinosinusitis with nasal polyps for Community-Care members.

    Policy Summary
    PayerCommunity-Care
    PolicyTezspire (tezepelumab) Medical Benefit Medication Utilization Policy
    Policy CodePolicy N/A
    Change TypeMinor / No material change
    Effective DateN/A
    Last ReviewDec 1, 2025
    Next Review DateDecember 2025
    Key ActionObtain prior authorization with documentation meeting initial approval criteria and confirm positive clinical response for continuation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥12minimum age for covered indications
    ≥2required asthma exacerbations (year)
    1/28 daysquantity limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 mo
    initial auth (asthma)
    J2356billing code

    Coverage Criteria for Tezepelumab (Tezspire)

    Initial Therapy - Severe asthma

    Covered when ALL of the following are met:

    Severe asthma initial approval criteria: (i) Age ≥ 12 years; (ii) Prescribed by, or in consultation with, an allergist, pulmonologist, or immunologist; (iii) Diagnosis of severe asthma; (iv) History of ≥2 asthma exacerbations requiring systemic corticosteroids or emergency department visit or hospitalization for asthma within the past year despite adherent use of either an inhaled corticosteroid plus one additional controller medication OR maximally tolerated ICS/LABA; (v) Prescriber attests that the patient is adherent to controller medications AND that tezepelumab will not be used in combination with another targeted immunomodulator product for asthma

    Initial Therapy - Chronic rhinosinusitis with nasal polyps

    Covered when ALL of the following are met:

    CRSwNP initial approval criteria: (i) Age ≥ 12 years; (ii) Prescribed by, or in consultation with, an allergist, immunologist, or otolaryngologist; (iii) Diagnosis of chronic rhinosinusitis with nasal polyposis lasting ≥12 weeks; (iv) Bilateral nasal polyposis confirmed by nasal endoscopy or sinus CT; (v) Trial of a nasal corticosteroid spray was ineffective, contraindicated, or not tolerated; (vi) Moderate to severe symptoms of nasal congestion, blockage, or obstruction (eg, loss of smell, rhinorrhea, or facial pain)

    Continuation Therapy - Severe asthma

    Covered when ALL of the following are met:

    Severe asthma continuation criteria: (i) Ongoing diagnosis of severe asthma; (ii) Positive clinical response has been achieved as documented by the prescriber; (iii) Tezepelumab will not be used in combination with another targeted immunomodulator product used for asthma

    Continuation Therapy - CRSwNP

    Covered when ALL of the following are met:

    CRSwNP continuation criteria: (i) Ongoing diagnosis of chronic rhinosinusitis with nasal polyposis; (ii) Positive clinical response has been achieved as documented by the prescriber

    Use of tezepelumab in combination with another targeted immunomodulator product used for asthma is not permitted. The prescriber must attest that the patient will not receive concomitant targeted asthma immunomodulator therapy as a condition of coverage.

    Billing and Coding

    Applicable HCPCS CodesHCPCS
    J2356Injection, tezepelumab-ekko, 1 mg

    Provider Requirements and Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization required with documentation meeting the initial approval criteria for the applicable indication. Continuation of therapy also requires prior authorization with documentation of positive clinical response and confirmation that tezepelumab will not be used in combination with another targeted immunomodulator for asthma.

    • Applies to indications: severe asthma and chronic rhinosinusitis with nasal polyps
    • Initial authorization: must meet the Coverage Determination Criteria for Initial Approval (age ≥12, specialist prescriber or consultation, diagnostic and trial history as applicable)
    • Continuation authorization: must document positive clinical response and ongoing eligibility per continuation criteria
    • Quantity limits: 1 prefilled syringe or pen per 28 days if approved
    • Authorization periods: initial — severe asthma 6 months, chronic rhinosinusitis with nasal polyps 4 months; continuation — 1 year
    Step Therapy

    Step Therapy / Prerequisite Controller Therapy

    Background

    Tezspire (tezepelumab) is a targeted immunomodulator indicated for treatment of severe asthma and for chronic rhinosinusitis with nasal polyps in patients ≥ 12 years of age. For severe asthma, coverage is targeted to patients with a diagnosis of severe asthma who have a history of ≥ 2 asthma exacerbations in the prior year requiring systemic corticosteroids, an emergency department visit, or hospitalization despite adherent use of either an inhaled corticosteroid plus one additional controller medication or a maximally tolerated ICS/LABA combination. For CRSwNP, the policy requires disease duration of at least 12 weeks, confirmation of bilateral nasal polyposis by nasal endoscopy or sinus CT, and a trial of a nasal corticosteroid spray that was ineffective, contraindicated, or not tolerated, with moderate to severe symptoms (for example loss of smell, rhinorrhea, or facial pain).

    Definitions and Clinical Terms

    Positive clinical response
    DefinitionClinically meaningful improvement in disease control or symptoms as documented by the prescriber (required for continuation of therapy).
    DocumentationPrescriber must attest to observed improvement in disease control or symptoms in medical record for continuation approvals.
    Role in continuationRequired element for continuation of therapy for both severe asthma and CRSwNP per policy continuation criteria.
    Severe asthma
    DefinitionAsthma with ≥2 exacerbations in the past year requiring systemic corticosteroids, emergency department visit, or hospitalization despite adherent controller therapy.
    Age requirementPatient must be ≥ 12 years of age for initial approval.
    Policy Summary
    PayerCommunity-Care
    PolicyTezspire (tezepelumab) Medical Benefit Medication Utilization Policy
    Policy CodePolicy N/A
    Change TypeMinor / No material change
    Effective DateN/A
    Last ReviewDec 1, 2025
    Next Review DateDecember 2025
    Key ActionObtain prior authorization with documentation meeting initial approval criteria and confirm positive clinical response for continuation.
    SourceLink
    On This Page
    Coverage Criteria for Tezepelumab (Tezspire)Billing and CodingProvider Requirements and AuthorizationBackgroundDefinitions and Clinical Terms

    For severe asthma, members must have a documented history of adherent use of an inhaled corticosteroid plus one additional controller medication, or maximally tolerated ICS/LABA combination, and have experienced ≥2 asthma exacerbations in the prior 12 months despite that controller therapy. Prescriber must be an allergist, pulmonologist, or immunologist, or there must be documentation of consultation. Prescriber must attest that tezepelumab will not be used concomitantly with another targeted immunomodulator for asthma.

    • Age requirement: ≥ 12 years
    • Exacerbation history: ≥ 2 exacerbations in past year requiring systemic corticosteroids, ED visit, or hospitalization despite controller adherence
    • Prescriber specialty: allergist, pulmonologist, or immunologist (or consult documented)
    • Attestation: adherence to controller meds and no concomitant targeted immunomodulator
    Documentation Required

    Required Documentation

    Documentation submitted with the prior authorization request must include the diagnosis (severe asthma or chronic rhinosinusitis with nasal polyposis), patient age (≥12), prescriber specialty or evidence of specialist consultation, relevant diagnostic confirmation (e.g., bilateral nasal polyposis on endoscopy or CT for CRSwNP), prior medication trials and intolerance/contraindication notes, and records supporting exacerbation history or positive clinical response as applicable.

    • For CRSwNP: confirmation of bilateral nasal polyposis by nasal endoscopy or sinus CT and trial of nasal corticosteroid spray (ineffective, contraindicated, or not tolerated)
    • For severe asthma: documentation of ≥2 exacerbations in past year despite controller adherence
    • Evidence of positive clinical response for continuation requests
    • Medication history and prescriber attestation regarding concomitant biologic use
    Denial Risk

    Triggers for Denial

    Requests may be denied if required documentation is missing or criteria are not met. Common triggers for denial include lack of documented exacerbation history despite controller adherence, absence of specialist prescriber or consultation, missing confirmation of bilateral nasal polyposis or failed/contraindicated nasal steroid trial for CRSwNP, or evidence of concurrent use with another targeted immunomodulator for asthma.

    • No documented ≥2 asthma exacerbations in past year despite adherent controller therapy
    • No specialist prescriber or documented consultation
    • For CRSwNP: no objective confirmation of bilateral nasal polyps or no trial of nasal corticosteroid documented
    • Request indicates concomitant use with another targeted immunomodulator for asthma
    Controller adherenceExacerbations must have occurred despite adherent utilization of either an inhaled corticosteroid plus one additional controller medication or maximally tolerated ICS/LABA.
    PrescriberMust be prescribed by, or in consultation with, an allergist, pulmonologist, or immunologist for initial approval.
    Chronic rhinosinusitis with nasal polyposis (CRSwNP)
    DefinitionChronic rhinosinusitis with bilateral nasal polyps lasting at least 12 weeks confirmed by nasal endoscopy or sinus CT.
    Age requirementPatient must be ≥ 12 years of age for initial approval.
    Symptom requirementModerate to severe symptoms of nasal congestion, blockage, or obstruction (eg loss of smell, rhinorrhea, or facial pain).
    Prior therapyTrial of a nasal corticosteroid spray that was ineffective, contraindicated, or not tolerated is required prior to approval.
    PrescriberMust be prescribed by, or in consultation with, an allergist, immunologist, or otolaryngologist for initial approval.